Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

SECTION 1.2

Description of the concentration

On 29 November 2016, the European Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No. 139/2004, by which Abbott Laboratories (Abbott) intends to acquire sole control over Alere Inc. (Alere) through a share acquisition.

Abbott is listed on the New York Stock Exchange (NYSE) and the Chicago Stock Exchange (CHX) and headquartered in Abbott Park, Illinois. Abbott focuses on the discovery, development, manufacture, and sale of a broad and diversified line of health care products. Abbott is active in the following segments: Established Pharmaceutical Products, Diagnostics Products, Nutritional Products and Vascular Products.

Alere is listed on the NYSE and headquartered in Waltham, Massachusetts. Alere produces professional diagnostic solutions for infectious disease, cardiometabolic disease and toxicology.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.